NO964871L - Nye agonistforbindelser - Google Patents

Nye agonistforbindelser

Info

Publication number
NO964871L
NO964871L NO964871A NO964871A NO964871L NO 964871 L NO964871 L NO 964871L NO 964871 A NO964871 A NO 964871A NO 964871 A NO964871 A NO 964871A NO 964871 L NO964871 L NO 964871L
Authority
NO
Norway
Prior art keywords
agonist compounds
new agonist
new
compounds
therapy
Prior art date
Application number
NO964871A
Other languages
English (en)
Norwegian (no)
Other versions
NO964871D0 (no
Inventor
Helmut Schmidhammer
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO964871L publication Critical patent/NO964871L/no
Publication of NO964871D0 publication Critical patent/NO964871D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO964871A 1994-05-18 1996-11-15 Nye agonistforbindelser NO964871D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401727A SE9401727D0 (sv) 1994-05-18 1994-05-18 New compounds I
PCT/SE1995/000504 WO1995031464A1 (fr) 1994-05-18 1995-05-09 Nouveaux composes agonistes

Publications (2)

Publication Number Publication Date
NO964871L true NO964871L (no) 1996-11-15
NO964871D0 NO964871D0 (no) 1996-11-15

Family

ID=20394058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964871A NO964871D0 (no) 1994-05-18 1996-11-15 Nye agonistforbindelser

Country Status (18)

Country Link
US (1) US5886001A (fr)
EP (1) EP0759923A1 (fr)
JP (1) JPH10500132A (fr)
CN (1) CN1152314A (fr)
AU (1) AU690281B2 (fr)
BR (1) BR9507656A (fr)
CA (1) CA2189139A1 (fr)
FI (1) FI964576A (fr)
HU (1) HU9603171D0 (fr)
IL (1) IL113627A0 (fr)
IS (1) IS4381A (fr)
NO (1) NO964871D0 (fr)
NZ (1) NZ287177A (fr)
PL (1) PL317250A1 (fr)
SE (1) SE9401727D0 (fr)
SK (1) SK139696A3 (fr)
WO (1) WO1995031464A1 (fr)
ZA (1) ZA953699B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197953T3 (es) * 1995-09-26 2004-01-16 Toray Industries, Inc. Derivados de indol y aplicaciones medicas de los mismos.
JP4110579B2 (ja) * 1997-01-16 2008-07-02 東レ株式会社 インドロモルヒナン誘導体および脳障害治療・予防剤
GB9717629D0 (en) * 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
WO2000008027A1 (fr) * 1998-08-06 2000-02-17 Regents Of The University Of Minnesota Antagonistes du recepteur opioide kappa (op2)
WO2002080919A1 (fr) * 2001-04-06 2002-10-17 Regents Of The University Of Minnesota Composes therapeutiques et procedes
US7232829B2 (en) 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
BRPI0415165A (pt) 2003-10-01 2007-01-09 Adolor Corp composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2399577A1 (fr) 2006-09-12 2011-12-28 Adolor Corporation Utilisation de composés spiro pour améliorer la fonction cognitive
US9321116B2 (en) * 2009-03-05 2016-04-26 United Technologies Corporation Cold metal transfer gas metal arc welding apparatus and method of operation
EP2340832A1 (fr) 2009-12-23 2011-07-06 Universität Innsbruck Composés de morphine-6-one pour le traitement ou la prévention des maladies neurodégénératives
US8987293B2 (en) 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
WO2014037832A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques
WO2013167990A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la dépression
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2013167992A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles inflammatoires
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168033A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et methodes pour le traitement de maladies neurologiques
WO2013168002A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
WO2013168005A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome des jambes sans repos et de la fibromyalgie
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168016A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur sévère
WO2013168012A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles respiratoires
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168015A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de l'asthme et de l'allergie
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
CA2873098A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la sclerose en plaques
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175344A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015082932A1 (fr) 2013-12-05 2015-06-11 The University Of Bath Nouveaux composés opioïdes et leurs utilisations
WO2016110865A1 (fr) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (fr) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
WO2016051420A1 (fr) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions et méthodes pour le traitement de la sclérose en plaques
EP3212626B1 (fr) 2014-10-27 2018-11-07 Cellix Bio Private Limited Séls á trois composants du ester monométhylique du acid fumarique avec pipérazine ou ethylene diamine pour le traitement de sclérose en plaques
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
EP3215154B1 (fr) 2014-11-07 2020-01-29 Regents of the University of Minnesota Sels et compositions utiles pour le traitement de maladie
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
WO2017165558A1 (fr) 2016-03-22 2017-09-28 Regents Of The University Of Minnesota Combinaison pour traiter la douleur

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP2906654B2 (ja) * 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5223507A (en) * 1992-01-21 1993-06-29 G. D. Searle & Co. Method of using opioid compounds as delta opioid selective agonist analgesics
NZ246687A (en) * 1992-01-23 1996-12-20 Toray Industries Morphinan derivative and pharmaceutical compositions thereof
EP0614898B1 (fr) * 1992-09-29 2003-05-07 Toray Industries, Inc. Derive indole, procede pour sa fabrication, et son usage medicinal
US5464841A (en) * 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders

Also Published As

Publication number Publication date
FI964576A0 (fi) 1996-11-15
AU2581895A (en) 1995-12-05
NO964871D0 (no) 1996-11-15
AU690281B2 (en) 1998-04-23
EP0759923A1 (fr) 1997-03-05
CN1152314A (zh) 1997-06-18
PL317250A1 (en) 1997-04-01
US5886001A (en) 1999-03-23
BR9507656A (pt) 1997-09-23
IS4381A (is) 1996-11-08
WO1995031464A1 (fr) 1995-11-23
CA2189139A1 (fr) 1995-11-23
SE9401727D0 (sv) 1994-05-18
FI964576A (fi) 1996-11-15
SK139696A3 (en) 1997-05-07
ZA953699B (en) 1995-11-20
HU9603171D0 (en) 1997-01-28
IL113627A0 (en) 1995-08-31
JPH10500132A (ja) 1998-01-06
NZ287177A (en) 1997-11-24

Similar Documents

Publication Publication Date Title
NO964871L (no) Nye agonistforbindelser
NO904839L (no) Fremgangsmaate for fremstilling av benzoxazinderivater.
TW332814B (en) Morphinan derivative
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
NO20023037D0 (no) Nye piperidin- og piperazinderivater
MX9707453A (es) Derivados de quinazolina.
GEP20043324B (en) Purine Derivatives
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
GEP20053476B (en) 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
SE9401728D0 (sv) New compounds II
NO996108L (no) 9-oksinerytromycinderivater
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
TR199700206A2 (xx) Floralkil- ve floralkoksi ikame edilmi� heterosiklik bradikinin-antagonistleri, bunlar�n imal edilmesine mahsus usul ve bunlar�n kullan�lmalar�.
NO178858C (no) Analogifremgangsmåte for fremstilling av substituerte 4-fenyl-4-piperidinkarboksamider med både lokal anestetisk og analgetisk effekt
NO20010654D0 (no) Ny anvendelse av taxoidderivater
NO982863L (no) Nye forbindelser med analgetisk effekt
TR199800478T1 (xx) Diarilalkenilamin t�revleri
NO306718B1 (no) Nye forbindelser med analgetisk og lokalanaestetisk effekt, farmasöytisk preparat inneholdende disse forbindelsene og deres anvendelse
IL102334A0 (en) 2-(1-piperidyl)ethanol derivatives,their preparation and their therapeutic application
NO913391L (no) Fremgangsmaate for fremstilling av nye hetrazepinoide syreamider.
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application